ReWalk Robotics’ (LFWD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a research report released on Thursday,Benzinga reports. The firm currently has a $13.00 target price on the stock.

Separately, Laidlaw assumed coverage on ReWalk Robotics in a research note on Monday, February 10th. They set a “buy” rating and a $10.00 price objective for the company.

ReWalk Robotics Price Performance

Shares of LFWD opened at $1.77 on Thursday. The company has a market cap of $18.76 million, a P/E ratio of -0.71 and a beta of 2.05. The stock has a fifty day moving average price of $1.74 and a 200 day moving average price of $2.40. ReWalk Robotics has a 12 month low of $1.25 and a 12 month high of $7.70.

Insider Transactions at ReWalk Robotics

In other news, major shareholder Global Fund Lp Lind II sold 381,676 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the sale, the insider now owns 1,049,430 shares in the company, valued at $3,526,084.80. This represents a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael Swinford acquired 21,622 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $2.03 per share, with a total value of $43,892.66. Following the acquisition, the director now owns 65,040 shares of the company’s stock, valued at approximately $132,031.20. This trade represents a 49.80 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 2.50% of the company’s stock.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.